Can Fite enrolls 1st patient in Phase IIb Namodenoson clinical trial
Category: #health  By Mateen Dalal  Date: 2022-02-02
  • share
  • Twitter
  • Facebook
  • LinkedIn

Can Fite enrolls 1st patient in Phase IIb Namodenoson clinical trial

Can Fite BioPharma, an advanced clinical stage biotechnology company ramping up pipeline of its proprietary small molecule drugs designed for inflammatory, cancer and liver diseases, has reportedly announced the enrollment of first patient in its Phase IIb study of Namodenoson for non-alcoholic steatohepatitis (NASH).

The Phase IIb clinical trial of its drug candidate Namodenoson is a randomized, multi-center, double-masked, placebo-centered study conducted in subjects diagnosed with biopsy-confirmed NASH.

Primary assessment stage of the study will focus on evaluating the efficacy of Namodenoson against that of placebo among 140 subjects with NASH, as standardized by a histological endpoint.

As a part of the study, eligible subjects are randomly aligned in 2:1 ratio, offered either 25 mg of Namodenoson dose orally every 12 hours or similar pattern of placebo for 36 weeks.

As of now, not a single NASH treatment has been approved by the U.S. FDA, while the increasing prevalence of the condition is estimated to drive the potential pharmaceutical market to approximately $35-$40 billion by 2025.

The U.S. National Institutes of Health highlights that incidences of NASH in the U.S. are seen among 2-5% of the American population.

Moreover, NASH is at the forefront of causative factors for liver transplant in women and the second to lead cause in both men and women in the U.S., notably to flag itself as the leading position in causes for liver transplants in men as well.

Dr. Pnina Fishman, CEO of Can-Fite, explained that the Phase IIa study rendered promising results associated with key liver fibrosis and NASH biomarkers and hence the biopharma anticipates similar therapeutic effect among a larger cohort of subjects tested using liver biopsy.

Currently, Can-Fite has already secured out-licensing agreements for its proprietary drug Namodenoson in the treatment of NASH in China, Eastern Europe, and South Korea, consisting of milestone payments structure along with double-digit royalties following approval and commercialization.  

Source Credit: https://www.businesswire.com/news/home/20220131005278/en/Can-Fite-Announces-First-Patient-Enrolled-in-Phase-IIb-NASH-Clinical-Trial-with-Namodenoson

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Meter nabs $38Mn to scale business & support faster enterprise internet
Meter nabs $38Mn to scale business & support faster enterprise internet
By Mateen Dalal

Meter, Inc., an internet & Wi-Fi infrastructure provider for businesses, has recently announced that it has successfully raised $38 million in a Series B funding round that was headed by Lachy Groom and Sequoia Capital. Industry leaders like D...

MakeMyTrip teams up with banks to offer ‘Book Now Pay Later’ option
MakeMyTrip teams up with banks to offer ‘Book Now Pay Later’ option
By Mateen Dalal

The BNPL (book now pay later) payment has been introduced on MakeMyTrip on bookings for flights, travel, or hotels as well as on the Goibibo app MakeMyTrip, the online travel company, has recently said that it has collaborated with 15 banks, finte...

BlackBerry collabs with Midis Group to expand Cybersecurity biz growth
BlackBerry collabs with Midis Group to expand Cybersecurity biz growth
By Mateen Dalal

BlackBerry Limited, a Canada-based software company focused on cybersecurity, has recently entered into a partnership with Midis Group, a leading technology company offering advanced hardware and software solutions, to expand its market footprint acr...